September 18, 2023
Avalyn Pharma’s CEO Leads Workshop on Clinical Strategy at IPF Summit
Avalyn CEO, Lyn Baranowski will lead a workshop during the IPF Summit on clinical trial strategies for pulmonary fibrosis therapies
September 12, 2023
Avalyn Pharma Presents Data Showing Favorable Tolerability and Potential of AP01 to Preserve Forced Vital Capacity in Adults with Pulmonary Fibrosis
Data were presented at ERS 2023 showing that treatment with AP01 preserved forced vital capacity in participants in the ongoing AP01-005 open label extension study.
September 11, 2023
Avalyn Pharma Appoints Business Operations Leader, Melissa Rhodes, to the Role of Chief Operating Officer
Avalyn appointed Melissa Rhodes, Ph.D., a business operations leader with extensive expertise in respiratory medicine, to the role of chief operating officer.
September 7, 2023
Avalyn Pharma’s Inhaled Pulmonary Fibrosis Programs to be Highlighted at Upcoming ERS International Congress
Interstitial lung disease experts will present FVC findings from Phase 1b ATLAS study of AP-01 at European Respiratory Society’s Congress
August 7, 2023
Avalyn Pharma Expands Executive Team with Appointment of Howard M. Lazarus, MD, FCCP to the Role of Chief Medical Officer
Avalyn announced that it has appointed pulmonary and critical care physician, Howard M. Lazarus, M.D., FCCP, to the newly created position of chief medical officer.
July 27, 2023
Avalyn Pharma Invited to Present at Canaccord Genuity Annual Growth Conference
Avalyn CEO Lyn Baranowski will participate in a fireside chat during the 2023 Canaccord Genuity Growth Conference August 10 in Boston
June 15, 2023
Avalyn Pharma Highlighting Inhalation Platform at Upcoming H.C. Wainwright and Hanson Wade Conferences in June
Avalyn leadership is presenting the corporate and produce development strategy at June conferences hosted by H.C. Wainwright and Hanson & Wade
May 23, 2023
Avalyn Pharma Made Corporate and Clinical Presentations at ATS 2023 Including Results of Long-Term Treatment of Pulmonary Fibrosis with AP01
Long-term efficacy and tolerability data presented by Avalyn at ATS 2023 indicate a durable and consistent response to AP01 therapy
May 11, 2023
Avalyn Pharma Showcasing Therapeutic Approach and Clinical Status at ATS 2023 and the Respiratory Innovation Summit (RIS)
Avalyn showcasing therapeutic approach to life-threatening respiratory diseases at upcoming ATS annual meeting being held May 19-24, 2023.
May 10, 2023
Avalyn Pharma Presenting at BioEquity Europe
Lyn Baranowski is planning to present a corporate update during BioEquity Europe, which is being held May 14-16, 2023 in Dublin, Ireland
April 11, 2023
Avalyn Pharma Reports Data After One Year of Treatment in Ongoing AP01 Open-label Extension Trial in Adults with Pulmonary Fibrosis
Top-line results are reported from the open-label extension trial of AP01 in participants with idiopathic and progressive pulmonary fibrosis
March 30, 2023
Avalyn Pharma Reports Results of Phase 1 Study of AP02 in Healthy Volunteers and Participants with Idiopathic Pulmonary Fibrosis
Top-line data from Phase 1 trial showed that AP02 (inhaled nintedanib) was well tolerated in healthy volunteers and adults with idiopathic pulmonary fibrosis (IPF)
March 23, 2023
Avalyn Pharma Publishes Phase 1b ATLAS Results Demonstrating Stabilization of Lung Function at 24 and 48 Weeks with AP01 and Favorable Safety Profile
Results from the Phase 1b ATLAS study of AP01 (inhaled pirfenidone) in adults with IPF were published online in the journal, Thorax.
November 28, 2022
Avalyn Pharma Invited to Participate in the Annual Evercore ISI HealthCONx Conference
Avalyn Pharma’s chief executive and chief financial officers will participate in a fireside chat during the annual Evercore ISI HealthCONx Conference
October 17, 2022
Avalyn Pharma Appoints Lyn Baranowski Chief Executive Officer
Avalyn welcomes CEO, Lyn Baranowski, who brings a career of respiratory disease experience from Altavant Sciences, Pearl Therapeutics and Novartis
October 27, 2021
Marc Schneebaum Joins Avalyn Pharma as Chief Financial Officer
Avalyn Pharma welcomes CFO, Marc Schneebaum, who brings financial strategy and business development experience from an array of biotechnology companies
May 24, 2021
Avalyn Pharma Reports Statistically Significant Dose Response with Aerosolized Pirfenidone in an Idiopathic Pulmonary Fibrosis Trial
Avalyn presented results from a Phase 1/2 study, in which lung function was maintained among the high-dose AP01 (inhaled pirfenidone) group
October 16, 2020
Avalyn Pharma Reports Update in Ongoing Idiopathic Pulmonary Fibrosis Trial
Avalyn Pharma announced completion of last patient in the initial 24 week evaluation of AP01 in a Phase 1/2 study
April 27, 2020
Avalyn Pharma Secures $35.5 Million Series B Financing, Broadens Development Portfolio
Avalyn Pharma announced the completion of a $35.5 million Series B round led by Norwest Venture Partner
May 15, 2017
Genoa Pharmaceuticals Secures $62 Million Series A Financing, Adds to Leadership Team
Genoa Pharmaceuticals completed a $62 million Series A financing led by F-Prime Capital Partners and Edmond de Rothschild Investment Partners
August 5, 2014
Genoa Pharmaceuticals Receives Orphan-Drug Designation for Pirfenidone in the Inhaled Treatment of Idiopathic Pulmonary Fibrosis (IPF)
The U.S. Food and Drug Administration has granted orphan-drug designation to Genoa for the use of pirfenidone in GP-101, the company's lead candidate for the treatment of IPF
May 13, 2014
Genoa Pharmaceuticals to Present at the Annual American Thoracic Society International Conference
Genoa Pharmaceuticals announced that it will highlight research conducted with inhaled GP-101 for the treatment of idiopathic pulmonary fibrosis during the 2014 American Thoracic Society International Conference
April 21, 2014
Genoa Pharmaceuticals and McMaster University Demonstrate Inhaled Pharmacokinetics Enables Improved Pirfenidone Activity With Significant Promise to Enhance IPF Treatment Safety and Tolerability
Genoa Pharmaceuticals reported results from an in vivo study of inhaled GP-101 in the treatment of pulmonary fibrosis